Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 18/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878755 | 0.90 | SSTR5 (0.59) | SSTR5DRD2DRD4DRD3HRH1 | |
| SCHEMBL1875726 | 0.90 | SSTR5 (0.55) | SSTR5DRD2DRD4DRD3HRH1 | |
| SCHEMBL1871503 | 0.87 | SSTR5 (0.48) | SSTR5HRH1HTR2B | |
| SCHEMBL1881344 | 0.87 | SSTR5 (0.53) | SSTR5DRD2DRD4DRD3HRH1 | |
| SCHEMBL1873570 | 0.87 | SSTR5 (0.60) | SSTR5HRH1HTR2B | |
| SCHEMBL1874084 | 0.86 | SSTR5 (0.49) | SSTR5DRD2DRD4DRD3HRH1 | |
| SCHEMBL1875960 | 0.86 | SSTR5 (0.65) | SSTR5HRH1HTR2B | |
| SCHEMBL1881804 | 0.86 | SSTR5 (0.61) | SSTR5HRH1HTR2B | |
| SCHEMBL1881001 | 0.86 | SSTR5 (0.61) | SSTR5HRH1HTR2B | |
| SCHEMBL1877373 | 0.85 | SSTR5 (0.63) | SSTR5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | claimed |
| CN-101511817-A | Pyridine-and quinoline-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | claimed |
| EP-2066658-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-10 | — | — | EP | claimed |
| WO-2008031735-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | claimed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | claimed |
| US-7939661-B2 | Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| CN-101511817-A | Pyridine-and quinoline-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2066658-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008031735-A1 | PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064697-A1 | PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES | SSTR5, SSTR3, NPY5R | SSTR5 1/4885DRD2 368/4885DRD4 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.